These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 3196378

  • 21. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo.
    von Meel JC.
    Arzneimittelforschung; 1985; 35(1A):284-8. PubMed ID: 4039168
    [Abstract] [Full Text] [Related]

  • 22. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL, Bitterman H, Lefer AM.
    Thromb Res; 1989 Feb 01; 53(3):327-38. PubMed ID: 2718150
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Protective actions of aprotinin in acute traumatic shock.
    Araki H, Lefer AM.
    Arch Int Pharmacodyn Ther; 1979 Oct 01; 241(2):316-23. PubMed ID: 316692
    [Abstract] [Full Text] [Related]

  • 25. Effect of sulmazole and pimobendan on contractility of skinned fibres from frog skeletal muscle.
    Piazzesi G, Morano I, Rüegg JC.
    Arzneimittelforschung; 1987 Oct 01; 37(10):1141-3. PubMed ID: 3435586
    [Abstract] [Full Text] [Related]

  • 26. Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium.
    Takahashi R, Shimazaki Y, Endoh M.
    J Pharmacol Exp Ther; 2001 Sep 01; 298(3):1060-6. PubMed ID: 11504803
    [Abstract] [Full Text] [Related]

  • 27. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H, Yanagisawa A, Lefer AM.
    Circ Shock; 1986 Sep 01; 20(1):1-11. PubMed ID: 2945667
    [Abstract] [Full Text] [Related]

  • 28. Effects of pimobendan (UD-CG 115 BS), a new positive inotropic agent, on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction.
    Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR.
    J Cardiovasc Pharmacol; 1988 Sep 01; 12(5):547-54. PubMed ID: 2468054
    [Abstract] [Full Text] [Related]

  • 29. Use of hypertonic saline in the treatment of hemorrhagic shock.
    Bitterman H, Triolo J, Lefer AM.
    Circ Shock; 1987 Sep 01; 21(4):271-83. PubMed ID: 3581442
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, Wahl J, Cohn JN, Sonnenblick EH, LeJemtel TH.
    Am Heart J; 1992 Jan 01; 123(1):95-103. PubMed ID: 1729854
    [Abstract] [Full Text] [Related]

  • 33. Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.
    Duncker DJ, Hartog JM, Levinsky L, Verdouw PD.
    Br J Pharmacol; 1987 Jul 01; 91(3):609-15. PubMed ID: 3607369
    [Abstract] [Full Text] [Related]

  • 34. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock.
    Aoki N, Siegfried M, Tsao P, Lento P, Lefer AM.
    Res Commun Chem Pathol Pharmacol; 1988 Jun 01; 60(3):275-89. PubMed ID: 3175328
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
    Chu KM, Hu OY, Shieh SM.
    Drug Metab Dispos; 1999 Jun 01; 27(6):701-9. PubMed ID: 10348800
    [Abstract] [Full Text] [Related]

  • 37. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate.
    van Meel JC, Entzeroth M, Redemann N, Haigh RM.
    Arzneimittelforschung; 1995 Feb 01; 45(2):136-41. PubMed ID: 7710434
    [Abstract] [Full Text] [Related]

  • 38. In vitro effect of pimobendan on platelet aggregation in dogs.
    Shipley EA, Hogan DF, Fiakpui NN, Magee AN, Green HW, Sederquist KA.
    Am J Vet Res; 2013 Mar 01; 74(3):403-7. PubMed ID: 23438115
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H, Phillips GR, Dragon G, Lefer AM.
    J Pharmacol Exp Ther; 1987 Jul 01; 242(1):8-14. PubMed ID: 3039116
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.